European Medicines Agency’s Committee for Medicinal Products for Human Use recommends marketing authorisation for idarucizumab (Praxbind), a specific reversal agent for dabigatran
On 24 September 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing... Read More
